On Nov 05, major Wall Street analysts update their ratings for $UpStream Bio (UPB.US)$, with price targets ranging from $38 to $75.
J.P. Morgan analyst Tessa Romero initiates coverage with a buy rating, and sets the target price at $38.
TD Cowen analyst Yaron Werber initiates coverage with a buy rating.
William Blair analyst Matt Phipps initiates coverage with a buy rating.
Piper Sandler analyst Yasmeen Rahimi initiates coverage with a buy rating, and sets the target price at $75.
Furthermore, according to the comprehensive report, the opinions of $UpStream Bio (UPB.US)$'s main analysts recently are as follows:
Upstream Bio's primary asset, verekitug, a recombinant human IgG1 monoclonal antibody targeting the thymic stromal lymphopoietin receptor, is being developed to address severe asthma, chronic rhinosinusinitis with nasal polyps, and COPD. It is anticipated that verekitug will be the main catalyst for the company's stock performance in the medium to long term as its clinical profile advances.
The initiation of coverage on Upstream Bio with a positive outlook is based on the company's verekitug, which is regarded as a 'differentiated fast follower.' This is due to its higher potency and longer dosing intervals compared to Tezspire. Furthermore, the Phase 1 data have demonstrated 'rapid, deep, and sustained effects' on asthma biomarkers.
Here are the latest investment ratings and price targets for $UpStream Bio (UPB.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月5日，多家华尔街大行更新了$UpStream Bio (UPB.US)$的评级，目标价介于38美元至75美元。
摩根大通分析师Tessa Romero首予买入评级，目标价38美元。
TD Cowen分析师Yaron Werber首予买入评级。
威廉博莱分析师Matt Phipps首予买入评级。
派杰投资分析师Yasmeen Rahimi首予买入评级，目标价75美元。
此外，综合报道，$UpStream Bio (UPB.US)$近期主要分析师观点如下：
Upstream Bio的核心资产vereckitug是一种重组的人IgG1单克隆抗体，瞄准胸腺stromal淋巴激素受体，正在研发用于治疗严重哮喘、慢性鼻窦炎并鼻息肉、以及COPD。预计vereckitug将会在公司股票中长期表现中是主要推动力，随着其临床资料进展。
对Upstream Bio展开覆盖并持积极展望的原因是该公司的vereckitug，被视为“不同寻常的快速追随者”。这是因为相对于Tezspire，它具有更高的效力和更长的用药间隔。此外，第1期数据已经表明对哮喘生物标志物具有“迅速、深远和持久的影响”。
以下为今日4位分析师对$UpStream Bio (UPB.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
